EGFR and non-small cell lung carcinoma: In a phase II clinical trial in South Korea, in NSCLC patients with brain metastases and EGFR-TKI sensitive mutations, an overall response rate of approximately 70–89% and overall survival (OS) of 15.9–21.9 months were achieved by treatment with erbtinib monotherapy [8].